Cover Image
市場調查報告書

Polyphor Ltd. :產品平台分析

Polyphor Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253788
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
Polyphor Ltd. :產品平台分析 Polyphor Ltd. - Product Pipeline Review - 2015
出版日期: 2015年04月30日 內容資訊: 英文 40 Pages
簡介

Polyphor Ltd. ha,循環系統疾病,感染疾病,腫瘤學,呼吸疾病,有著所說的免疫學,遺傳性疾病等的所謂7大治療領域和對未公佈的疾病的有潛力的臨床藥候補。該公司對這些的化合物的開發投入力量,為了是這樣的疾病的症狀有大的市場需求,根據那個治療的化合物患者有,並且能受到新的方便的可能性能製藥公司間的合作生出價值。

本報告提供Polyphor Ltd. 提供著的治療藥開發平台的現狀及各開發階段比較分析,藥物標的,作用機制,給藥途徑,各分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Polyphor Ltd.的基本資料

  • Polyphor Ltd.概要
  • 主要資訊
  • 企業資料

Polyphor Ltd.:R&D概要

  • 主要的治療範圍

Polyphor Ltd.:開發平台(管線)的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Polyphor Ltd.:開發中產品概況

  • 臨床實驗階段有的開發中產品
    • 第二階段有的產品/聯合治療模式
    • 第一階段有的產品/聯合治療模式
  • 初期階段有的開發中產品
    • 在前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Polyphor Ltd.:藥物簡介

  • POL-6326
  • POL-5551
  • POL-6014
  • POL-6926
  • POL-7080 Follow-On
  • POL-7085
  • Small Molecule for Undisclosed Indication
  • Small Molecules for Infectious Diseases
  • Synthetic Peptide to Agonize FPR1/2 for Infectious Disease and Immunology
  • Synthetic Peptide to Antagonize FPR1/2 for Infectious Disease and Immunology

Polyphor Ltd.:開發平台分析

  • 按標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Polyphor Ltd.:最近的開發平台趨勢

Polyphor Ltd.:暫停中的計劃

Polyphor Ltd.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07003CDB

Summary

Global Markets Direct's, 'Polyphor Ltd. - Product Pipeline Review - 2015', provides an overview of the Polyphor Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Polyphor Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Polyphor Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Polyphor Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Polyphor Ltd.'s pipeline products

Reasons to buy

  • Evaluate Polyphor Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Polyphor Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Polyphor Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Polyphor Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Polyphor Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Polyphor Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Polyphor Ltd. Snapshot
    • Polyphor Ltd. Overview
    • Key Information
    • Key Facts
  • Polyphor Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Polyphor Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Polyphor Ltd. - Pipeline Products Glance
    • Polyphor Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Polyphor Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Polyphor Ltd. - Drug Profiles
    • POL-6326
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • POL-5551
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • POL-6014
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • POL-6926
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • POL-7080 Follow-On
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • POL-7085
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Infectious Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Agonize FPR1/2 for Infectious Disease and Immunology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize FPR1/2 for Infectious Disease and Immunology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Polyphor Ltd. - Pipeline Analysis
    • Polyphor Ltd. - Pipeline Products by Target
    • Polyphor Ltd. - Pipeline Products by Route of Administration
    • Polyphor Ltd. - Pipeline Products by Molecule Type
    • Polyphor Ltd. - Pipeline Products by Mechanism of Action
  • Polyphor Ltd. - Recent Pipeline Updates
  • Polyphor Ltd. - Dormant Projects
  • Polyphor Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Polyphor Ltd., Key Information
  • Polyphor Ltd., Key Facts
  • Polyphor Ltd. - Pipeline by Indication, 2015
  • Polyphor Ltd. - Pipeline by Stage of Development, 2015
  • Polyphor Ltd. - Monotherapy Products in Pipeline, 2015
  • Polyphor Ltd. - Partnered Products in Pipeline, 2015
  • Polyphor Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Polyphor Ltd. - Out-Licensed Products in Pipeline, 2015
  • Polyphor Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Polyphor Ltd. - Phase II, 2015
  • Polyphor Ltd. - Phase I, 2015
  • Polyphor Ltd. - Preclinical, 2015
  • Polyphor Ltd. - Discovery, 2015
  • Polyphor Ltd. - Pipeline by Target, 2015
  • Polyphor Ltd. - Pipeline by Route of Administration, 2015
  • Polyphor Ltd. - Pipeline by Molecule Type, 2015
  • Polyphor Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Polyphor Ltd. - Recent Pipeline Updates, 2015
  • Polyphor Ltd. - Dormant Developmental Projects,2015

List of Figures

  • Polyphor Ltd. - Pipeline by Top 10 Indication, 2015
  • Polyphor Ltd. - Pipeline by Stage of Development, 2015
  • Polyphor Ltd. - Monotherapy Products in Pipeline, 2015
  • Polyphor Ltd. - Pipeline by Top 10 Target, 2015
  • Polyphor Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Polyphor Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Polyphor Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top